EUA Fact Sheet-PI-Providers-Prime-12y+

FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING
VACCINE (VACCINATION PROVIDERS)

EMERGENCY USE AUTHORIZATION (EUA) OF
THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019
(COVID-19)
PRIMARY SERIES
For 12 Years and Older
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use
Authorization (EUA) to permit the emergency use of the unapproved product, MODERNA
COVID-19 VACCINE, for active immunization to prevent COVID-19 in individuals 6
months of age and older.
This Fact Sheet pertains only to Moderna COVID-19 Vaccine supplied in a multiple-dose
vial with a red cap and a label with a light blue border which is authorized for use to
provide:
• a two-dose primary series to individuals 12 years of age and older; and
• a third primary series dose to individuals 12 years of age and older with certain
kinds of immunocompromise.1
SPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made

by ModernaTX, Inc. that is indicated for active immunization to prevent COVID-19 in
individuals 18 years of age and older.2 It is approved for use as a two-dose primary series
for the prevention of COVID-19 in individuals 18 years of age and older. It is also
authorized for emergency use to provide:
• a two-dose primary series to individuals 12 years through 17 years of age; and
• a third primary series dose to individuals 12 years of age and older with certain
kinds of immunocompromise.
SPIKEVAX (COVID-19, mRNA) and Moderna COVID-19 Vaccine supplied in multiple-

dose vials with a red cap and a label with a light blue border intended for use in individuals
12 years of age and older should not be used in individuals 6 months through 11 years of
1
Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who
are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
2
As described in the Letter of Authorization, the FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the
EUA-authorized presentation of the Moderna COVID-19 Vaccine supplied in multiple-dose vials with red caps and
labels with a light blue border can be used interchangeably to provide primary series doses to individuals 12 years of
age and older without presenting any safety or effectiveness concerns.
Revised: Dec/8/2022 1
age because of the potential for vaccine administration errors, including dosing errors.3,4
SUMMARY OF INSTRUCTIONS FOR COVID-19 VACCINATION PROVIDERS

Vaccination providers enrolled in the federal COVID-19 Vaccination Program must report all
vaccine administration errors, all serious adverse events, cases of myocarditis, cases of
pericarditis, cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and
cases of COVID-19 that result in hospitalization or death following administration of the
Moderna COVID-19 Vaccine. See “MANDATORY REQUIREMENTS FOR MODERNA
COVID-19 VACCINE ADMINISTRATION UNDER EMERGENCY USE
AUTHORIZATION” for reporting requirements.
The Moderna COVID-19 Vaccine is a suspension for intramuscular injection.
Primary Series5
Each primary series dose of the Moderna COVID-19 Vaccine for individuals 12 years of age and
older is 0.5 mL.
The Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label
with a light blue border is administered as a primary series of two doses (0.5 mL each) 1 month
apart to individuals 12 years of age or older.
A third primary series dose (0.5 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-
dose vial with a red cap and a label with a light blue border is authorized for administration at
least 1 month following the second dose to individuals at least 12 years of age with certain kinds
of immunocompromise.
See this Fact Sheet for instructions for preparation and administration. This Fact Sheet may have
been updated. For the most recent Fact Sheet, please see www.modernatx.com/covid19vaccine-
eua.
For information on clinical trials that are testing the use of the Moderna COVID-19 Vaccine for
active immunization against COVID-19, please see www.clinicaltrials.gov.
3
Notwithstanding the age limitations for use of the different presentations of the Moderna COVID-19 Vaccine,
individuals who will turn from 11 years to 12 years of age between doses in the primary series may receive, for any
dose in the primary series, either: (1) the Moderna COVID-19 Vaccine authorized for use in individuals 6 years
through 11 years of age (each 0.5 mL dose containing 50 mcg mRNA) supplied in multiple-dose vials with dark
blue caps and labels with a purple border stating “BOOSTER DOSES ONLY”; (2) SPIKEVAX (COVID-19
Vaccine, mRNA) or the Moderna COVID-19 Vaccine authorized for use in individuals 12 years of age and older
(each 0.5 mL dose containing 100 mcg mRNA) supplied in multiple-dose vials with red caps and labels with a light
blue border; or (3) the Moderna COVID-19 Vaccine authorized for use in individuals 6 years through 11 years of
age (each 0.5 mL dose containing 50 mcg mRNA) supplied in multiple-dose vials with dark blue caps and labels
with a teal border (currently not available). The multiple-dose vials with dark blue caps and labels with a purple
border are authorized to provide 0.5 mL primary series doses for individuals 6 years through 11 years of age.
4
For primary vaccination of individuals 6 months through 5 years of age and 6 years through 11 years of age, refer
to the respective Moderna COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine.
5
A primary series dose of SPIKEVAX (COVID-19 Vaccine, mRNA) is 0.5 mL.
DESCRIPTION OF COVID-19
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel coronavirus,
SARS-CoV-2, that appeared in late 2019. It is predominantly a respiratory illness that can affect
other organs. People with COVID-19 have reported a wide range of symptoms, ranging from
mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus.
Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle and body
aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or
vomiting; diarrhea.
DOSAGE AND ADMINISTRATION
Storage and Handling

The information in this Fact Sheet supersedes the information on the vial and carton labels.
During storage, minimize exposure to room light, and avoid exposure to direct sunlight and
ultraviolet light.
Frozen Storage
Store frozen between -50°C to -15°C (-58°F to 5°F).
Storage after Thawing

• Storage at 2°C to 8°C (36°F to 46°F):
o Vials may be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30
days prior to first use.
o Vials should be discarded 12 hours after the first puncture.
o Vials may be stored between 8°C to 25°C (46°F to 77°F) for a total of 24 hours.
o Total storage at 8°C to 25°C (46°F to 77°F) must not exceed 24 hours.
Do not refreeze once thawed.
Thawed vials can be handled in room light conditions.
Transportation of Thawed Vials at 2°C to 8°C (36°F to 46°F)
If transport at -50°C to -15°C (-58°F to 5°F) is not feasible, available data support transportation
of one or more thawed vials for up to 12 hours at 2°C to 8°C (36°F to 46°F) when shipped using
shipping containers which have been qualified to maintain 2°C to 8°C (36°F to 46°F) and under
routine road and air transport conditions with shaking and vibration minimized. Once thawed and
transported at 2°C to 8°C (36°F to 46°F), vials should not be refrozen and should be stored at
2°C to 8°C (36°F to 46°F) until use.
Dose and Schedule
Primary Series6
older is 0.5 mL.
of immunocompromise.
Preparation for Administration

• The Moderna COVID-19 Vaccine multiple-dose vial with a red cap and a label with a
light blue border is supplied in two volumes:
o multiple-dose vial containing 5.5 mL
light blue border contains a frozen suspension that does not contain a preservative and
must be thawed prior to administration.
• Verify that the vial of Moderna COVID-19 Vaccine has a red cap and a label with light
blue border.
• Thaw each vial before use following the instructions below.
6
Thawing Instructions for Moderna COVID-19 Vaccine Multiple-Dose Vials with
Red Caps and Labels with a Light Blue Border
Multiple-Dose Thaw in Refrigerator Thaw at Room Temperature

Vial
Containing
5.5 mL Thaw between 2°C to 8°C (36°F Alternatively, thaw between

to 46°F) for 2 hours and 30 15°C to 25°C (59°F to 77°F)
minutes. Let each vial stand at for 1 hour.
room temperature for 15
minutes before administering.
to 46°F) for 3 hours. Let each 15°C to 25°C (59°F to 77°F)
vial stand at room temperature for 1 hour and 30 minutes.
for 15 minutes before
administering.
• After thawing, do not refreeze.

• Swirl vial gently after thawing and between each withdrawal. Do not shake. Do not
dilute the vaccine.
• Parenteral drug products should be inspected visually for particulate matter and
discoloration prior to administration, whenever solution and container permit.
• The Moderna COVID-19 Vaccine is a white to off-white suspension. It may contain
white or translucent product-related particulates. Do not administer if vaccine is
discolored or contains other particulate matter.
• Primary series doses of 0.5 mL may be extracted from vials with red caps and labels with
a light blue border, preferentially using low dead-volume syringes and/or needles.
• When extracting primary series doses, depending on the syringes and needles used, a
maximum of 11 doses (range: 10-11 doses) may be extracted from the vial containing 5.5
mL or a maximum of 15 doses (range: 13-15 doses) may be extracted from the vial
containing 7.5 mL.
• If the amount of vaccine remaining in the vial cannot provide a primary series dose (0.5
mL), discard the vial and contents. Do not pool excess vaccine from multiple vials.
• After the first dose has been withdrawn, the vial should be held between 2°C to 25°C
(36°F to 77°F). Record the date and time of first use on the Moderna COVID-19 Vaccine
vial label. Discard vial after 12 hours. Do not refreeze.
Administration
Administer the Moderna COVID-19 Vaccine intramuscularly.
CONTRAINDICATION
Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a
severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19
Vaccine (see Full EUA Prescribing Information).
WARNINGS
Management of Acute Allergic Reactions

Appropriate medical treatment to manage immediate allergic reactions must be immediately
available in the event an acute anaphylactic reaction occurs following administration of the
Moderna COVID-19 Vaccine.
Monitor Moderna COVID-19 Vaccine recipients for the occurrence of immediate adverse
reactions according to the Centers for Disease Control and Prevention (CDC) guidelines
(https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).
Myocarditis and Pericarditis

Postmarketing data with Moderna COVID-19 Vaccine demonstrate increased risks of
myocarditis and pericarditis, particularly within the period 0 through 7 days following the second
dose of the primary series. The observed risk is highest in males 18 through 24 years of age.
Although some cases required intensive care support, available data from short-term follow-up
suggest that most individuals have had resolution of symptoms with conservative management.
Information is not yet available about potential long-term sequelae.
Some, but not all, observational analyses of postmarketing data suggest that there may be an
increased risk of myocarditis and pericarditis in males under 40 years of age following the
second dose of the Moderna COVID-19 Vaccine relative to other authorized or approved mRNA
COVID-19 vaccines.
The CDC has published considerations related to myocarditis and pericarditis after vaccination,
including for vaccination of individuals with a history of myocarditis or pericarditis
(https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).
Syncope
Syncope (fainting) may occur in association with administration of injectable vaccines.
Procedures should be in place to avoid injury from fainting.
Altered Immunocompetence
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may
have a diminished immune response to the Moderna COVID-19 Vaccine.
Limitations of Vaccine Effectiveness

The Moderna COVID-19 Vaccine may not protect all vaccine recipients.
ADVERSE REACTIONS
Adverse Reactions in Clinical Trials

Adverse reactions reported in clinical trials following administration of the Moderna COVID-19
Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills,
nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, erythema at
the injection site, and rash. (See Full EUA Prescribing Information)
Adverse Reactions in Post-Authorization Experience
Anaphylaxis and other severe allergic reactions, myocarditis, pericarditis, syncope, and urticaria
have been reported following administration of the Moderna COVID-19 Vaccine during post-
authorization use.
Additional adverse reactions, some of which may be serious, may become apparent with more
widespread use of the Moderna COVID-19 Vaccine.
USE WITH OTHER VACCINES

There is no information on the co-administration of the Moderna COVID-19 Vaccine with other
vaccines.
INFORMATION TO PROVIDE TO VACCINE RECIPIENTS/CAREGIVERS

As the vaccination provider, you must communicate to the recipient or their caregiver,
information consistent with the “Vaccine Information Fact Sheet for Recipients and Caregivers”
(and provide a copy or direct the individual to the website www.modernatx.com/covid19vaccine-
eua to obtain the Fact Sheet) prior to the individual receiving each dose of the Moderna COVID-
19 Vaccine, including:
• FDA has authorized the emergency use of the Moderna COVID-19 Vaccine, which is not
an FDA-approved vaccine.
• There is an option to accept or refuse the Moderna COVID-19 Vaccine.
• The significant known and potential risks and benefits of the Moderna COVID-19
Vaccine, and the extent to which such risks and benefits are unknown.
• Information about available alternative vaccines and the risks and benefits of those
alternatives.
For information on clinical trials that are evaluating the use of the Moderna COVID-19 Vaccine
to prevent COVID-19, please see www.clinicaltrials.gov.
Provide a vaccination card to the recipient or their caregiver with the date when the recipient
needs to return for the second dose of Moderna COVID-19 Vaccine.
Provide the v-safe information sheet to vaccine recipients/caregivers and encourage vaccine
recipients to participate in v-safe. V-safe is a voluntary smartphone-based tool that uses text
messaging and web surveys to check in with people who have been vaccinated to identify
potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC monitor
the safety of COVID-19 vaccines. V-safe also provides dose reminders if needed and live
telephone follow-up by CDC if participants report a significant health impact following COVID-
19 vaccination. For more information, visit: www.cdc.gov/vsafe.
MANDATORY REQUIREMENTS FOR MODERNA COVID-19 VACCINE

ADMINISTRATION UNDER EMERGENCY USE AUTHORIZATION7
In order to mitigate the risks of using this unapproved product under EUA and to optimize the
7
Vaccination providers administering SPIKEVAX (COVID-19 Vaccine, mRNA) must adhere to the same reporting
requirements.
potential benefit of the Moderna COVID-19 Vaccine, the following items are required. Use of
unapproved Moderna COVID-19 Vaccine for active immunization to prevent COVID-19 under
this EUA is limited to the following (all requirements must be met):
1. The Moderna COVID-19 Vaccine is authorized for use in individuals 6 months of age
and older.
2. The vaccination provider must communicate to the individual receiving the Moderna
COVID-19 Vaccine or their caregiver information consistent with the “Vaccine
Information Fact Sheet for Recipients and Caregivers” prior to the individual receiving
the Moderna COVID-19 Vaccine.
3. The vaccination provider must include vaccination information in the state/local

jurisdiction’s Immunization Information System (IIS) or other designated system.
4. The vaccination provider is responsible for mandatory reporting of the following to the
Vaccine Adverse Event Reporting System (VAERS):
• vaccine administration errors whether or not associated with an adverse event,
• serious adverse events* (irrespective of attribution to vaccination),
• cases of myocarditis,
• cases of pericarditis,
• cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and
• cases of COVID-19 that result in hospitalization or death.
Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html.

For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should
include the words “Moderna COVID-19 Vaccine EUA” in the description section of the
report.
5. The vaccination provider is responsible for responding to FDA requests for information
about vaccine administration errors, adverse events, cases of myocarditis, cases of
pericarditis, cases of MIS in adults and children, and cases of COVID-19 that result in
hospitalization or death following administration of the Moderna COVID-19 Vaccine to
recipients.
*Serious adverse events are defined as:

• Death;
• A life-threatening adverse event;
• Inpatient hospitalization or prolongation of existing hospitalization;
• A persistent or significant incapacity or substantial disruption of the ability to
conduct normal life functions;
• A congenital anomaly/birth defect;
• An important medical event that based on appropriate medical judgement may
jeopardize the individual and may require medical or surgical intervention to
prevent one of the outcomes listed above.
OTHER ADVERSE EVENT REPORTING TO VAERS AND MODERNATX, INC.
Vaccination providers may report to VAERS other adverse events that are not required to be
reported using the contact information above.
To the extent feasible, report adverse events to ModernaTX, Inc. using the contact information
below or by providing a copy of the VAERS form to ModernaTX, Inc.
Email Fax number Telephone number
[email protected] 1-866-599-1342 1-866-MODERNA

(1-866-663-3762)
ADDITIONAL INFORMATION
For general questions, visit the website or call the telephone number provided below.
To access the most recent Moderna COVID-19 Vaccine Fact Sheets, please scan the QR code or
visit the website provided below.
Website Telephone number

www.modernatx.com/covid19vaccine-eua 1-866-MODERNA
(1-866-663-3762)
AVAILABLE ALTERNATIVES
SPIKEVAX (COVID-19 Vaccine, mRNA) and COMIRNATY (COVID-19 Vaccine, mRNA)
are FDA-approved vaccines to prevent COVID-19 caused by SARS-CoV-2. There may be
clinical trials or availability under EUA of other COVID-19 vaccines.
FEDERAL COVID-19 VACCINATION PROGRAM

This vaccine is being made available for emergency use exclusively through the CDC COVID-
19 Vaccination Program (the Vaccination Program). Healthcare providers must enroll as
providers in the Vaccination Program and comply with the provider requirements. Vaccination
providers may not charge any fee for the vaccine and may not charge the vaccine recipient any
out-of-pocket charge for administration. However, vaccination providers may seek appropriate
reimbursement from a program or plan that covers COVID-19 vaccine administration fees for
the vaccine recipient (private insurance, Medicare, Medicaid, HRSA COVID-19 Uninsured
Program for non-insured recipients). For information regarding provider requirements and
enrollment in the CDC COVID-19 Vaccination Program, see
https://www.cdc.gov/vaccines/covid-19/provider-enrollment.html.
Individuals becoming aware of any potential violations of the CDC COVID-19 Vaccination
Program requirements are encouraged to report them to the Office of the Inspector General, U.S.
Department of Health and Human Services, at 1-800-HHS-TIPS or TIPS.HHS.GOV.
AUTHORITY FOR ISSUANCE OF THE EUA

The Secretary of the Department of Health and Human Services (HHS) has declared a public
health emergency that justifies the emergency use of drugs and biological products during the
COVID-19 Pandemic. In response, the FDA has issued an EUA for the unapproved product,
Moderna COVID-19 Vaccine, and for certain uses of FDA-approved SPIKEVAX (COVID-19
Vaccine, mRNA) for active immunization to prevent COVID-19.
FDA issued this EUA, based on ModernaTX, Inc.’s request and submitted data.
For the authorized uses, although limited scientific information is available, based on the totality
of the scientific evidence available to date, it is reasonable to believe that the Moderna COVID-
19 Vaccine and SPIKEVAX (COVID-19 Vaccine, mRNA) may be effective for the prevention
of COVID-19 in individuals as specified in the Full EUA Prescribing Information.
This EUA for the Moderna COVID-19 Vaccine and SPIKEVAX (COVID-19 Vaccine, mRNA)
will end when the Secretary of HHS determines that the circumstances justifying the EUA no
longer exist or when there is a change in the approval status of the product such that an EUA is
no longer needed.
For additional information about Emergency Use Authorization, visit FDA at:
https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-
framework/emergency-use-authorization.
COUNTERMEASURES INJURY COMPENSATION PROGRAM

The Countermeasures Injury Compensation Program (CICP) is a federal program that has been
created to help pay for related costs of medical care and other specific expenses to compensate
people injured after use of certain medical countermeasures. Medical countermeasures are
specific vaccines, medications, devices, or other items used to prevent, diagnose, or treat the
public during a public health emergency or a security threat. For more information about CICP
regarding the vaccines to prevent COVID-19, visit http://www.hrsa.gov/cicp, email
[email protected], or call: 1-855-266-2427.
Moderna US, Inc.

Cambridge, MA 02139
©2022 ModernaTX, Inc. All rights reserved.

Patent(s): www.modernatx.com/patents
Revised: Dec/8/2022
END SHORT VERSION FACT SHEET

Long Version (Full EUA Prescribing Information) Begins On Next Page
FULL EMERGENCY USE AUTHORIZATION (EUA)
PRESCRIBING INFORMATION
MODERNA COVID-19 VACCINE
FULL EUA PRESCRIBING INFORMATION: CONTENTS* 11 USE IN SPECIFIC POPULATIONS

1 AUTHORIZED USE 11.1 Pregnancy
2 DOSAGE AND ADMINISTRATION 11.2 Lactation
2.1 Preparation for Administration 11.3 Pediatric Use
2.2 Administration 11.4 Geriatric Use
2.3 Dose and Schedule 11.5 Use in Immunocompromised Individuals
3 DOSAGE FORMS AND STRENGTHS 13 DESCRIPTION
4 CONTRAINDICATIONS 14 CLINICAL PHARMACOLOGY
5 WARNINGS AND PRECAUTIONS 14.1 Mechanism of Action
5.1 Management of Acute Allergic Reactions 18 CLINICAL TRIAL RESULTS AND SUPPORTING DATA
5.2 Myocarditis and Pericarditis FOR EUA
5.3 Syncope 18.1 Efficacy of Two-Dose Primary Series in Participants 18 Years
5.4 Altered Immunocompetence of Age and Older
5.5 Limitations of Vaccine Effectiveness 18.2 Effectiveness of Two-Dose Primary Series in Participants 12
6 OVERALL SAFETY SUMMARY Years Through 17 Years of Age
6.1 Clinical Trials Experience 18.3 Immunogenicity of a Third Primary Series Dose in Individuals
6.2 Post-Authorization Experience with Certain Kinds of Immunocompromise
8 REQUIREMENTS AND INSTRUCTIONS FOR 19 HOW SUPPLIED/STORAGE AND HANDLING
REPORTING ADVERSE EVENTS AND VACCINE 20 PATIENT COUNSELING INFORMATION
ADMINISTRATION ERRORS 21 CONTACT INFORMATION
10 DRUG INTERACTIONS *Sections or subsections omitted from the full prescribing
information are not listed
______________________________________________________________________________
FULL EMERGENCY USE AUTHORIZATION (EUA) PRESCRIBING INFORMATION
1 AUTHORIZED USE
Moderna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization
(EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age
and older.
This EUA Prescribing Information pertains only to Moderna COVID-19 Vaccine supplied in a
multiple-dose vial with a red cap and a label with a light blue border which is authorized for use
for primary series doses in individuals 12 years of age and older.
2 DOSAGE AND ADMINISTRATION
For intramuscular injection only.
The storage, preparation, and administration information in this Prescribing Information apply to
the Moderna COVID-19 Vaccine, supplied in a multiple-dose vials with red caps and labels with
a light blue border, which is authorized for use for primary series doses in individuals 12 years of
age and older.
2.1 Preparation for Administration
light blue border is supplied in two volumes:
light blue border contains a frozen suspension that does not contain a preservative and
must be thawed prior to administration.
• Verify that the vial of Moderna COVID-19 Vaccine has a red cap and a label with light
blue border.
• Thaw each vial before use following the instructions below.
Thawing Instructions for Moderna COVID-19 Vaccine Multiple-Dose Vials with

Red Caps and Labels with a Light Blue Border
Multiple-Dose Thaw in Refrigerator Thaw at Room Temperature

Vial
Containing

to 46°F) for 2 hours and 30 15°C to 25°C (59°F to 77°F)
minutes. Let each vial stand at for 1 hour.
room temperature for 15
minutes before administering.
to 46°F) for 3 hours. Let each 15°C to 25°C (59°F to 77°F)
vial stand at room temperature for 1 hour and 30 minutes.
for 15 minutes before
administering.
• After thawing, do not refreeze.

• Swirl vial gently after thawing and between each withdrawal. Do not shake. Do not
dilute the vaccine.
• Parenteral drug products should be inspected visually for particulate matter and
discoloration prior to administration, whenever solution and container permit.
• The Moderna COVID-19 Vaccine is a white to off-white suspension. It may contain
white or translucent product-related particulates. Do not administer if vaccine is
discolored or contains other particulate matter.
• Primary series doses of 0.5 mL may be extracted from vials with red caps and labels with
a light blue border, preferentially using low dead-volume syringes and/or needles.
• When extracting primary series doses, depending on the syringes and needles used, a
maximum of 11 doses (range: 10-11 doses) may be extracted from the vial containing 5.5
mL or a maximum of 15 doses (range: 13-15 doses) may be extracted from the vial
containing 7.5 mL.
• If the amount of vaccine remaining in the vial cannot provide a primary series dose (0.5
mL), discard the vial and contents. Do not pool excess vaccine from multiple vials.
• After the first dose has been withdrawn, the vial should be held between 2°C to 25°C
(36°F to 77°F). Record the date and time of first use on the Moderna COVID-19 Vaccine
vial label. Discard vial after 12 hours. Do not refreeze.
2.2 Administration
Administer the Moderna COVID-19 Vaccine intramuscularly.
2.3 Dose and Schedule
Primary Series8
older is 0.5 mL.
of immunocompromise.9
3 DOSAGE FORMS AND STRENGTHS
Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a
light blue border is a suspension for injection.
• Each primary series dose is 0.5 mL.
4 CONTRAINDICATIONS
Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of
severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19
Vaccine [see Description (13)].
5 WARNINGS AND PRECAUTIONS
5.1 Management of Acute Allergic Reactions
Appropriate medical treatment to manage immediate allergic reactions must be immediately

available in the event an acute anaphylactic reaction occurs following administration of the
Moderna COVID-19 Vaccine.
8
9
Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who
are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
Monitor Moderna COVID-19 Vaccine recipients for the occurrence of immediate adverse
reactions according to the Centers for Disease Control and Prevention (CDC) guidelines
(https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).
5.2 Myocarditis and Pericarditis
Postmarketing data with Moderna COVID-19 Vaccine demonstrate increased risks of

myocarditis and pericarditis, particularly within the period 0 through 7 days following the second
dose of the primary series. The observed risk is highest in males 18 through 24 years of age.
Although some cases required intensive care support, available data from short-term follow-up
suggest that most individuals have had resolution of symptoms with conservative management.
Information is not yet available about potential long-term sequelae.
Some, but not all, observational analyses of postmarketing data suggest that there may be an
increased risk of myocarditis and pericarditis in males under 40 years of age following the
second dose of the Moderna COVID-19 Vaccine relative to other authorized or approved mRNA
COVID-19 vaccines.
The CDC has published considerations related to myocarditis and pericarditis after vaccination,
including for vaccination of individuals with a history of myocarditis or pericarditis
(https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).
5.3 Syncope
Syncope (fainting) may occur in association with administration of injectable vaccines.

Procedures should be in place to avoid injury from fainting.
5.4 Altered Immunocompetence
Immunocompromised persons, including individuals receiving immunosuppressive therapy, may

have a diminished response to the Moderna COVID-19 Vaccine.
5.5 Limitations of Vaccine Effectiveness
The Moderna COVID-19 Vaccine may not protect all vaccine recipients.
6 OVERALL SAFETY SUMMARY
It is MANDATORY for vaccination providers to report to the Vaccine Adverse Event

Reporting System (VAERS) all vaccine administration errors, all serious adverse events,
cases of myocarditis, cases of pericarditis, cases of Multisystem Inflammatory Syndrome
(MIS) in adults and children, and hospitalized or fatal cases of COVID-19 following
vaccination with the Moderna COVID-19 Vaccine.10 To the extent feasible, provide a copy
10
Vaccination providers administering SPIKEVAX (COVID-19 Vaccine, mRNA) must adhere to the same
reporting requirements.
of the VAERS form to ModernaTX, Inc. Please see the REQUIREMENTS AND
INSTRUCTIONS FOR REPORTING ADVERSE EVENTS AND VACCINE
ADMINISTRATION ERRORS section for details on reporting to VAERS and
ModernaTX, Inc.
Primary Series
In a clinical study, the adverse reactions in participants 18 years of age and older following
administration of the primary series included pain at the injection site (92.0%), fatigue (70.0%),
headache (64.7%), myalgia (61.5%), arthralgia (46.4%), chills (45.4%), nausea/vomiting
(23.0%), axillary swelling/tenderness (19.8%), fever (15.5%), swelling at the injection site
(14.7%), and erythema at the injection site (10.0%).
In a clinical study, the adverse reactions in participants 12 years through 17 years of age
following administration of the primary series included pain at the injection site (97.2%),
headache (78.4%), fatigue (75.2%), myalgia (54.3%), chills (49.1%), arthralgia (34.6%), axillary
swelling/tenderness (34.6%), nausea/vomiting (29.3%), swelling at the injection site (27.7%),
erythema at the injection site (25.8%), and fever (13.7%).
Post-Authorization Experience
Anaphylaxis and other severe allergic reactions, myocarditis, pericarditis, syncope, and urticaria
have been reported following administration of the Moderna COVID-19 Vaccine outside of
clinical trials.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical
trials of another vaccine and may not reflect the rates observed in practice.
Overall, 39,000 participants aged 6 months and older received at least one dose of Moderna
COVID-19 Vaccine in five clinical trials (NCT04283461, NCT04405076, NCT04470427,
NCT04649151, and NCT04796896). In a sixth clinical trial (NCT04885907), 60 solid organ
transplant recipients received a third dose of Moderna COVID-19 Vaccine.
Study 1 (NCT04470427) is a Phase 3 randomized, placebo-controlled, observer-blind clinical

trial conducted in the United States involving 30,346 participants 18 years of age and older who
received at least one dose of Moderna COVID-19 Vaccine11 (n=15,184) or placebo (n=15,162).
Study 3 (NCT04649151) is a Phase 2/3 randomized, placebo-controlled, observer-blind, clinical
trial conducted in the United States involving 3,726 participants 12 years through 17 years of age
who received at least one dose of Moderna COVID-19 Vaccine (n=2,486) or placebo (n=1,240).
Study 4 (NCT04796896) includes an ongoing Phase 2/3 randomized, placebo-controlled,
observer-blind clinical trial component conducted in the United States and Canada involving
11
Moderna COVID-19 Vaccine is marketed as SPIKEVAX (COVID-19 Vaccine, mRNA), which is approved for
use in individuals 18 years of age and older.
10,390 participants 6 months through 11 years of age who received at least one dose of Moderna
COVID-19 Vaccine (n=7,799) or placebo (n=2,591).
Participants 18 Years of Age and Older
The safety of Moderna COVID-19 Vaccine was evaluated in an ongoing Phase 3 randomized,
placebo-controlled, observer-blind clinical trial conducted in the United States involving 30,346
participants 18 years of age and older who received at least one dose of Moderna COVID-19
Vaccine (n=15,184) or placebo (n=15,162) (Study 1, NCT04470427). Upon issuance of the
Emergency Use Authorization (December 18, 2020) for Moderna COVID-19 Vaccine,
participants were unblinded in a phased manner over a period of months to offer placebo
participants Moderna COVID-19 Vaccine. The median duration of follow up for safety after the
second injection during the blinded phase was 4 months. The median duration of follow up for
safety after the second injection including both the blinded phase and the open-label phase was 6
months.
In Study 1, the median age of the population was 52 years (range 18-95); 22,826 (75.2%)
participants were 18 to 64 years of age and 7,520 (24.8%) participants were 65 years of age and
older. Overall, 52.6% of the participants were male, 47.4% were female, 20.5% were Hispanic or
Latino, 79.2% were White, 10.2% were African American, 4.6% were Asian, 0.8% were
American Indian or Alaska Native, 0.2% were Native Hawaiian or Pacific Islander, 2.0% were
other races, and 2.1% were Multiracial. Demographic characteristics were similar between
participants who received Moderna COVID-19 Vaccine and those who received placebo.
Solicited Adverse Reactions
Local and systemic adverse reactions and use of antipyretic medication were solicited in an
electronic diary for 7 days following each injection (i.e., day of vaccination and the next 6 days)
among participants receiving Moderna COVID-19 Vaccine (n=15,179) and participants
receiving placebo (n=15,159) with at least 1 documented dose. Events that persisted for more
than 7 days were followed until resolution. Solicited adverse reactions were reported more
frequently among vaccine participants than placebo participants.
The reported number and percentage of the solicited local and systemic adverse reactions by age
group and dose are presented in Table 1 and Table 2, respectively.
Table 1: Number and Percentage of Participants With Solicited Local and Systemic
Adverse Reactions Starting Within 7 Days* After Each Dose in Participants 18 Years
Through 64 Years (Solicited Safety Set, Dose 1 and Dose 2)†
Moderna COVID-19 Vaccine Placeboa
Dose 1 Dose 2 Dose 1 Dose 2

(N=11,406) (N=11,000) (N=11,402) (N=10,929)
n (%) n (%) n (%) n (%)
Local Adverse
Reactions
Pain 9,908 9,893 2,183 2,048
(86.9) (89.9) (19.1) (18.7)
Pain, Grade 3b 366 506 23 22
(3.2) (4.6) (0.2) (0.2)
Axillary 1,322 1,777 567 474
swelling/tenderness (11.6) (16.2) (5.0) (4.3)
Axillary 37 47 13 12
swelling/tenderness, (0.3) (0.4) (0.1) (0.1)
Grade 3b
Swelling (hardness) 766 1,399 42 46
≥25 mm (6.7) (12.7) (0.4) (0.4)
Swelling (hardness), 62 183 3 5
Grade 3c (0.5) (1.7) (<0.1) (<0.1)
Erythema (redness) 354 989 54 53
≥25 mm (3.1) (9.0) (0.5) (0.5)
Erythema (redness), 34 210 11 12
Grade 3c (0.3) (1.9) (<0.1) (0.1)
Systemic Adverse
Reactions
Fatigue 4,385 7,453 3,281 2,701
(38.5) (67.8) (28.8) (24.7)
Fatigue, Grade 3d 121 1,178 83 88
(1.1) (10.7) (0.7) (0.8)
Fatigue, Grade 4e 1 0 0 0
(<0.1) (0) (0) (0)
Headache 4,028 6,929 3,303 2,775
(35.3) (63.0) (29.0) (25.4)
Headache, Grade 3f 220 559 163 132
(1.9) (5.1) (1.4) (1.2)
Myalgia 2,700 6,789 1,625 1,425
(23.7) (61.7) (14.3) (13.0)
Myalgia, Grade 3d 74 1,116 38 42
(0.6) (10.1) (0.3) (0.4)
Arthralgia 1,892 5,010 1,327 1,180
(16.6) (45.6) (11.6) (10.8)
Arthralgia, Grade 3d 47 650 30 37
(0.4) (5.9) (0.3) (0.3)
Arthralgia, Grade 4e 1 0 0 0
(<0.1) (0) (0) (0)
Chills 1,050 5,357 730 662
(9.2) (48.7) (6.4) (6.1)
Chills, Grade 3g 17 164 8 15
(0.1) (1.5) (<0.1) (0.1)

(N=11,406) (N=11,000) (N=11,402) (N=10,929)
n (%) n (%) n (%) n (%)
Nausea/vomiting 1,068 2,355 908 807
(9.4) (21.4) (8.0) (7.4)
Nausea/vomiting, 6 11 8 8
Grade 3h (<0.1) (0.1) (<0.1) (<0.1)
Fever 102 1,909 37 38
(0.9) (17.4) (0.3) (0.3)
Fever, Grade 3i 10 185 1 2
(<0.1) (1.7) (<0.1) (<0.1)
Fever, Grade 4j 4 12 4 2
(<0.1) (0.1) (<0.1) (<0.1)
Use of antipyretic or 2,656 6,307 1,523 1,254
pain medication (23.3) (57.3) (13.4) (11.5)
* 7 days included day of vaccination and the subsequent 6 days. Events and use of antipyretic or pain medication
were collected in the electronic diary (e-diary).
† Absence of rows for Grade 4 adverse reactions indicates no events were reported.
a
Placebo was a saline solution.
b
Grade 3 pain and axillary swelling/tenderness: Defined as any use of prescription pain reliever; prevents daily
activity.
c
Grade 3 swelling and erythema: Defined as >100 mm / >10 cm.
d
Grade 3 fatigue, myalgia, arthralgia: Defined as significant; prevents daily activity.
e
Grade 4 fatigue, arthralgia: Defined as requires emergency room visit or hospitalization.
f
Grade 3 headache: Defined as significant; any use of prescription pain reliever or prevents daily activity.
g
Grade 3 chills: Defined as prevents daily activity and requires medical intervention.
h
Grade 3 nausea/vomiting: Defined as prevents daily activity; requires outpatient intravenous hydration.
i
Grade 3 fever: Defined as ≥39.0° – ≤40.0°C / ≥102.1° – ≤104.0°F.
j
Grade 4 fever: Defined as >40.0°C / >104.0°F.
Adverse Reactions Starting Within 7 Days* After Each Dose in Participants 65 Years and
Older (Solicited Safety Set, Dose 1 and Dose 2)†

(N=3,760) (N=3,691) (N=3,749) (N=3,649)
n (%) n (%) n (%) n (%)
Local Adverse
Reactions
Pain 2,780 3,071 482 438
(73.9) (83.2) (12.9) (12.0)
Pain, Grade 3b 50 100 32 19
(1.3) (2.7) (0.9) (0.5)
Axillary 231 315 155 97
Axillary 12 21 14 8
swelling/tenderness, (0.3) (0.6) (0.4) (0.2)
Grade 3b

(N=3,760) (N=3,691) (N=3,749) (N=3,649)
n (%) n (%) n (%) n (%)
Swelling (hardness) 169 408 23 14
≥25 mm (4.5) (11.1) (0.6) (0.4)
Grade 3c (0.5) (2.0) (<0.1) (0.2)
≥25 mm (2.4) (7.7) (0.6) (0.4)
Grade 3c (0.2) (2.1) (<0.1) (<0.1)
Systemic Adverse
Reactions
Fatigue 1,251 2,154 852 717
(33.3) (58.4) (22.7) (19.6)
Fatigue, Grade 3d 30 255 22 20
(0.8) (6.9) (0.6) (0.5)
Headache 922 1,708 723 652
(24.5) (46.3) (19.3) (17.9)
Headache, Grade 3e 53 107 34 33
(1.4) (2.9) (0.9) (0.9)
Myalgia 742 1,740 444 399
(19.7) (47.2) (11.9) (10.9)
Myalgia, Grade 3d 17 205 9 10
(0.5) (5.6) (0.2) (0.3)
Arthralgia 618 1,293 457 399
(16.4) (35.1) (12.2) (10.9)
(0.3) (3.4) (0.2) (0.2)
Chills 201 1,143 148 151
(5.3) (31.0) (4.0) (4.1)
Chills, Grade 3f 7 27 6 2
(0.2) (0.7) (0.2) (<0.1)
Nausea/vomiting 194 439 167 134
(5.2) (11.9) (4.5) (3.7)
Grade 3g (0.1) (0.3) (0.1) (<0.1)
Grade 4h (0) (<0.1) (0) (0)
Fever 10 367 7 5
(0.3) (9.9) (0.2) (0.1)
(<0.1) (0.5) (<0.1) (0)
(0) (<0.1) (<0.1) (<0.1)
Use of antipyretic or 673 1,548 477 331
pain medication (17.9) (41.9) (12.7) (9.1)
a
b
activity.
c
d
e
f
g
Grade 3 nausea/vomiting: Defined as prevents daily activity; requires outpatient intravenous hydration.
h
Grade 4 nausea/vomiting: Defined as requires emergency room visit or hospitalization for hypotensive shock.
i
j
Solicited local and systemic adverse reactions reported following administration of Moderna
COVID-19 Vaccine had a median duration of 1 to 3 days.
Grade 3 solicited local adverse reactions were more frequently reported after Dose 2 than after
Dose 1. Solicited systemic adverse reactions were more frequently reported by vaccine recipients
after Dose 2 than after Dose 1.
In Study 1, 2.3% of participants (vaccine=347, placebo=337) had evidence of prior SARS-CoV-

2 infection at baseline (immunologic or virologic evidence of prior SARS-CoV-2 infection
[defined as positive RT-PCR test and/or positive Elecsys immunoassay result at Day 1]).
Overall, among the 347 vaccine participants, there were no notable differences in reactogenicity
compared to the 14,750 vaccine participants who had no evidence of prior SARS-CoV-2
infection at baseline (negative RT-PCR test and negative Elecsys immunoassay result at Day 1).
Unsolicited Adverse Events
Participants were monitored for unsolicited adverse events for 28 days following each dose.
Serious adverse events and medically attended adverse events will be recorded for the entire
study duration (2 years). Among the 30,346 participants who had received at least 1 dose of
vaccine (N=15,184) or placebo (N=15,162), unsolicited adverse events that occurred within 28
days following any vaccination were reported by 31.3% of participants (n=4,752) who received
Moderna COVID-19 Vaccine and 28.6% of participants (n=4,338) who received placebo.
During the 28-day follow-up period following any dose, lymphadenopathy-related events were
reported by 1.7% of vaccine recipients and 0.8% of placebo recipients. These events included
lymphadenopathy, lymphadenitis, lymph node pain, vaccination-site lymphadenopathy,
injection-site lymphadenopathy, and axillary mass. This imbalance is consistent with the
imbalance observed for solicited axillary swelling/tenderness at the injected arm.
During the 7-day follow-up period of any vaccination, hypersensitivity events of injection site
rash or injection site urticaria, likely related to vaccination, were reported by 6 participants in the
Moderna COVID-19 Vaccine group and none in the placebo group. Delayed injection site
reactions that began >7 days after vaccination were reported in 1.4% of vaccine recipients and
0.7% of placebo recipients. Delayed injection site reactions included pain, erythema, and
swelling and are likely related to vaccination.
In the blinded portion of the study, there were 8 reports of facial paralysis (including Bell’s
palsy) in the Moderna COVID-19 Vaccine group, and 3 in the placebo group. In the 28-day
follow-up period there were two cases of facial paralysis in the Moderna COVID-19 Vaccine
group, which occurred on 8 and 22 days, respectively, after vaccination, and one in the placebo
group, which occurred 17 days after vaccination. Currently available information on facial
paralysis is insufficient to determine a causal relationship with the vaccine.
In the blinded portion of the study, there were 50 reports of herpes zoster in the Moderna
COVID-19 Vaccine group, and 23 in the placebo group. In the 28-day period after any
vaccination, there were 22 cases of herpes zoster in the Moderna COVID-19 Vaccine group, and
15 in the placebo group. Currently available information on herpes zoster infection is insufficient
to determine a causal relationship with the vaccine.
There were no other notable patterns or numerical imbalances between treatment groups for
specific categories of adverse events (including other neurologic, neuro-inflammatory, and
thrombotic events) that would suggest a causal relationship to Moderna COVID-19 Vaccine.
Serious Adverse Events
During the blinded phase of the study, serious adverse events were reported by 1.8% (n=268) of
participants who received Moderna COVID-19 Vaccine and 1.9% (n=292) of participants who
received placebo.
There were three serious adverse events of angioedema/facial swelling in the vaccine group in
recipients with a history of injection of dermatological fillers. The onset of swelling was reported
1-2 days after the second dose and was likely related to vaccination.
There were no other notable patterns or imbalances between treatment groups for specific
categories of serious adverse events (including neurologic, neuro-inflammatory, and thrombotic
events) that would suggest a causal relationship to Moderna COVID-19 Vaccine.
Participants 12 Years Through 17 Years of Age
Safety data for Moderna COVID-19 Vaccine in adolescents were collected in an ongoing Phase
2/3 randomized, placebo-controlled, observer-blind, clinical trial conducted in the United States
involving 3,726 participants 12 years through 17 years of age who received at least one dose of
Moderna COVID-19 Vaccine (n=2,486) or placebo (n=1,240) (Study 3, NCT04649151).
Overall, 51.4% were male, 48.6% were female, 11.6% were Hispanic or Latino, 83.9% were
White, 3.4% were African American, 5.9% were Asian, 0.5% were American Indian or Alaska
Native, <0.1% were Native Hawaiian or Pacific Islander, 1.0% were other races, and 4.5% were
Multiracial. Demographic characteristics were similar among participants who received Moderna
COVID-19 Vaccine and those who received placebo.
Solicited Adverse Reactions
Local and systemic adverse reactions and use of antipyretic medication were solicited in an
electronic diary for 7 days following each injection (i.e., day of vaccination and the next 6 days)
among participants receiving Moderna COVID-19 Vaccine (n=2,485) and participants receiving
placebo (n=1,240) with at least 1 documented dose. Events that persisted for more than 7 days
were followed until resolution.
The reported number and percentage of the solicited local and systemic adverse reactions in
participants 12 years through 17 years of age by dose are presented in Table 3.
Adverse Reactions Starting Within 7 Days* After Each Dose in Participants 12 Years
Through 17 Years (Solicited Safety Set, Dose 1 and Dose 2)†

(N=2,482) (N=2,478) (N=1,238) (N=1,220)
n (%) n (%) n (%) n (%)
Local Adverse
Reactions
Pain 2,310 2,290 431 370
(93.1) (92.4) (34.8) (30.3)
Pain, Grade 3b 133 126 1 3
(5.4) (5.1) (<0.1) (0.2)
Axillary 578 519 101 61
Axillary 10 7 0 0
swelling/tenderness, (0.4) (0.3) (0) (0)
Grade 3b
≥25 mm (16.2) (20.5) (1.0) (1.0)
Grade 3c (1.1) (2.3) (0) (0)
≥25 mm (13.5) (19.5) (0.6) (0.9)
Grade 3c (0.8) (2.9) (0) (0)
Systemic Adverse
Reactions
Fatigue 1,188 1,679 453 353
(47.9) (67.8) (36.6) (28.9)
Fatigue, Grade 3d 33 188 18 10
(1.3) (7.6) (1.5) (0.8)
Headache 1,106 1,739 477 370
(44.6) (70.2) (38.5) (30.3)
(2.3) (4.5) (1.4) (1.1)
Headache, Grade 4f 0 1 0 0
(0) (<0.1) (0) (0)
Myalgia 668 1,154 205 153
(26.9) (46.6) (16.6) (12.5)
Myalgia, Grade 3d 24 129 10 3
(1.0) (5.2) (0.8) (0.2)
Arthralgia 371 716 143 113
(15.0) (28.9) (11.6) (9.3)

(N=2,482) (N=2,478) (N=1,238) (N=1,220)
n (%) n (%) n (%) n (%)
(0.6) (2.3) (0.4) (0.2)
Chills 456 1,066 138 97
(18.4) (43.0) (11.1) (8.0)
Chills, Grade 3g 4 11 1 0
(0.2) (0.4) (<0.1) (0)
(11.3) (23.9) (8.9) (8.7)
Grade 3h (<0.1) (<0.1) (0) (0)
Grade 4i (0) (<0.1) (0) (0)
Fever 63 302 12 12
(2.5) (12.2) (1.0) (1.0)
(0.4) (1.9) (<0.1) (<0.1)
Fever, Grade 4k 0 1 0 1
(0) (<0.1) (0) (<0.1)
Use of antipyretic or 748 1,242 118 108
pain medication (30.1) (50.1) (9.5) (8.9)
a
b
activity.
c
d
e
f
Grade 4 headache: Defined as requires emergency room visit or hospitalization.
g
h
Grade 3 nausea/vomiting: Defined as prevents daily activity, requires outpatient intravenous hydration.
i
j
k
Solicited local and systemic adverse reactions reported following administration of Moderna
COVID-19 Vaccine had a median duration of 1 to 3 days.
An assessment of reactogenicity among participants with evidence of prior SARS-CoV-2

infection (immunologic or virologic evidence of prior SARS-CoV-2 infection [defined as
positive RT-PCR test and/or positive Elecsys immunoassay result at Day 1]) compared to those
with no evidence of infection at baseline (negative RT-PCR test and negative Elecsys
immunoassay result at Day 1) was conducted. In ages 12 years through 17 years, 5.8% of
participants (vaccine=147, placebo=69) had evidence of prior SARS-CoV-2 infection at
baseline. Table 4 presents the number and percentage of the solicited local and systemic adverse
reactions in Moderna COVID-19 Vaccine participants starting within 7 days after each dose by
SARS-CoV-2 status.
Table 4: Number and Percentage of Participants 12 Years Through 17 Years Who

Received Vaccine With Solicited Local and Systemic Adverse Reactions Starting Within 7
Days* After Each Dose by SARS-CoV-2 Status (Solicited Safety Set, Dose 1 and Dose 2)†
Baseline SARS-CoV-2 Baseline SARS-CoV-2

Positive Negative
(N=147) (N=146) (N=2,163) (N=2,162)
n (%) n (%) n (%) n (%)
Local Adverse
Reactions
Pain 128 124 2,023 2,006
(87.1) (84.9) (93.5) (92.8)
Pain, Grade 3a 9 7 113 114
(6.1) (4.8) (5.2) (5.3)
Axillary 58 25 487 465
Axillary 1 0 9 7
swelling/tenderness, (0.7) (0) (0.4) (0.3)
Grade 3a
≥25 mm (16.3) (15.1) (16.6) (20.8)
Grade 3b (2.7) (1.4) (1.0) (2.3)
≥25 mm (12.9) (12.3) (14.2) (20.0)
Grade 3b (0.7) (2.1) (0.9) (2.9)
Systemic Adverse
Reactions
Fatigue 103 94 1,004 1,470
(70.1) (64.4) (46.4) (68.0)
Fatigue, Grade 3c 4 5 27 173
(2.7) (3.4) (1.2) (8.0)
Headache 103 90 938 1,527
(70.1) (61.6) (43.4) (70.6)
Headache, Grade 3d 11 7 44 96
(7.5) (4.8) (2.0) (4.4)
(0) (0) (0) (<0.1)
Myalgia 63 63 557 1,017
(42.9) (43.2) (25.8) (47.1)
Myalgia, Grade 3c 3 2 19 117
(2.0) (1.4) (0.9) (5.4)
Arthralgia 36 39 305 633
(24.5) (26.7) (14.1) (29.3)
Arthralgia, Grade 3c 2 0 12 52
(1.4) (0) (0.6) (2.4)
Chills 72 63 363 934
(49.0) (43.2) (16.8) (43.2)
Chills, Grade 3f 0 0 4 10
(0) (0) (0.2) (0.5)
Baseline SARS-CoV-2 Baseline SARS-CoV-2
Positive Negative
(N=147) (N=146) (N=2,163) (N=2,162)
n (%) n (%) n (%) n (%)
(20.4) (19.9) (11.0) (24.2)
Grade 3g (0) (0) (<0.1) (<0.1)
Grade 4h (0) (0.7) (0) (0)
Fever 29 20 33 262
(19.7) (13.7) (1.5) (12.1)
(2.7) (1.4) (0.2) (1.9)
(0) (0) (0) (<0.1)
* 7 days included day of vaccination and the subsequent 6 days. Events were collected in the electronic diary (e-
diary).
a
activity.
b
c
d
e
Grade 4 headache: Defined as requires emergency room visit or hospitalization.
f
g
Grade 3 nausea/vomiting: Defined as prevents daily activity, requires outpatient intravenous hydration.
h
i
j
Participants were monitored for unsolicited adverse events for up to 28 days following each
dose. Serious adverse events and medically attended adverse events will be recorded for the
entire study duration. As of May 8, 2021, among participants who had received at least 1 dose of
vaccine or placebo (vaccine=2,486, placebo=1,240), unsolicited adverse events that occurred
within 28 days following each vaccination were reported by 20.5% of participants (n=510) who
received Moderna COVID-19 Vaccine and 15.9% of participants (n=197) who received placebo.
In these analyses, 97.3% of study participants had at least 28 days of follow-up after Dose 2.
A 14-year-old male experienced probable myocarditis with onset of symptoms 1 day after Dose
2 of Moderna COVID-19 Vaccine. Symptoms resolved after 8 days and no sequelae were
observed at 5 months. There were no cases of myocarditis among placebo recipients.
During the 28-day follow-up period following any dose, lymphadenopathy-related events that
were not necessarily captured in the 7-day e-diary were reported by 5.0% of vaccine recipients
and 0.5% of placebo recipients. These events included lymphadenopathy, vaccination-site
lymphadenopathy and injection-site lymphadenopathy which were plausibly related to
vaccination. This imbalance is consistent with the imbalance observed for solicited axillary
swelling/tenderness in the injected arm.
During the 28-day follow-up period following any dose, hypersensitivity adverse events were
reported in 1.8% of vaccine recipients and 0.6% of placebo recipients. Hypersensitivity events in
the vaccine group included injection site rash and injection site urticaria, which are likely related
to vaccination. Delayed injection site reactions that began >7 days after vaccination were
reported in 0.9% of vaccine recipients and in no placebo recipients. Delayed injection site
reactions included pain, erythema, and swelling and are likely related to vaccination.
specific categories of adverse events that would suggest a causal relationship to Moderna
COVID-19 Vaccine.
As of May 8, 2021, serious adverse events were reported by 0.2% (n=6) of participants who
received Moderna COVID-19 Vaccine and 0.2% (n=2) of participants who received placebo. In
these analyses, 97.3% of study participants had at least 28 days of follow-up after Dose 2, and
the median follow-up time for all participants was 53 days after Dose 2.
There were no notable patterns or imbalances between treatment groups for specific categories of
serious adverse events that would suggest a causal relationship to Moderna COVID-19 Vaccine.
Additional Safety Analyses
Study 3 participants started to enter an open-label, observational phase after May 10, 2021. A
long-term safety analysis was conducted in participants from Study 3 who received Moderna
COVID-19 Vaccine (n=2,486) with a cut-off date of January 31, 2022. In these analyses, the
median duration of follow-up including both the blinded and open-label phases was 312 days
after Dose 2 and 95.6% of study participants have had at least 6 months of follow-up after Dose
2. Through the cut-off date, there were no serious adverse events causally related to the vaccine.
Participants 6 Years Through 11 Years of Age
Safety data for Moderna COVID-19 Vaccine from Study 4 included data in 4,002 participants 6
years through 11 years of age who received at least one dose of Moderna COVID-19 Vaccine
(n=3,007) or placebo (n=995). As of the data cutoff date of November 10, 2021, the median
duration of blinded follow-up for safety was 51 days after Dose 2, and 1,284 participants had
been followed for at least 2 months after Dose 2 (vaccine=1,006, placebo=218).
Demographic characteristics in Study 4 were similar among participants who received Moderna
COVID-19 Vaccine and those who received placebo. Overall, 50.8% were male, 49.2% were
female, 18.5% were Hispanic or Latino, 65.6% were White, 10.0% were African American,
9.9% were Asian, 0.4% were American Indian or Alaska Native, <0.1% were Native Hawaiian
or Pacific Islander, 2.1% were other races, and 10.6% were Multiracial.
Participants were monitored for unsolicited adverse events for up to 28 days following each
dose. Serious adverse events and medically attended adverse events will be recorded for the
entire study duration. As of November 10, 2021, among participants who had received at least 1
dose of vaccine or placebo (vaccine=3,007, placebo=995), unsolicited adverse events that
occurred within 28 days following each vaccination were reported by 29.6% of participants
(n=891) who received Moderna COVID-19 Vaccine and 25.1% of participants (n=250) who
received placebo. In these analyses, 98.6% of study participants had at least 28 days of follow-up
after Dose 2.
reported by 1.8% of vaccine recipients and 0.6% of placebo recipients. These events included
lymphadenopathy, lymph node pain, injection-site lymphadenopathy, and vaccination-site
lymphadenopathy which were plausibly related to vaccination.
reported in 4.3% of vaccine recipients and 2.1% of placebo recipients. Hypersensitivity events in
the vaccine group included injection site rash and injection site urticaria, which are likely related
to vaccination. Delayed injection site reactions that began >7 days after vaccination were
reported in 2.7% of vaccine recipients and in 0.2% of placebo recipients. Delayed injection site
reactions included pain, erythema, and swelling and are likely related to vaccination.
During the 28-day follow-up period following any dose, events of abdominal pain (including
abdominal pain, abdominal pain upper, and abdominal pain lower) were reported by 1.1% of
vaccine recipients and 0.6% of placebo recipients. Currently available information is insufficient
to determine a causal relationship with the vaccine.
COVID-19 Vaccine.
As of November 10, 2021, serious adverse events were reported by 0.2% (n=6) of participants
who received Moderna COVID-19 Vaccine and 0.2% (n=2) participants who received placebo.
None of the events in the Moderna COVID-19 Vaccine group were considered related to
vaccine. In these analyses, 98.6% of study participants had at least 28 days of follow-up after
Dose 2, and the median follow-up time for all participants was 51 days after Dose 2.
There were no notable patterns or imbalances between treatment groups for specific categories of
serious adverse events that would suggest a causal relationship to Moderna COVID-19 Vaccine.
Additional Safety Analyses
Participants 6 years through 11 years in Study 4 started to enter an open-label, observational

phase after November 1, 2021. A long-term safety analysis was conducted in participants 6 years
through 11 years from Study 4 who received Moderna COVID-19 Vaccine (n=3,007) with a cut-
off date of February 21, 2022. In these analyses, the median duration of follow-up including both
the blinded and open-label phases was 158 days after Dose 2. Through the cut-off date, there
were no serious adverse events causally related to the vaccine.
Participants 6 Months Through 5 Years of Age
Safety data for Moderna COVID-19 Vaccine from Study 4 included data in 6,388 participants 6
months through 5 years of age who received at least one dose of Moderna COVID-19 Vaccine
(n=4,792) or placebo (n=1,596). As of the data cutoff date of February 21, 2022, the median
duration of blinded follow-up for safety for participants 6 months through 23 months was 68
days after Dose 2. For participants 2 years to 5 years, the median duration of blinded follow-up
for safety was 71 days after Dose 2.
For participants 6 months through 23 months, 51.1% were male, 48.9% were female, 13.2%
were Hispanic or Latino, 79.0% were White, 3.1% were African American, 4.9% were Asian,
0.2% were American Indian or Alaska Native, 0.0% were Native Hawaiian or Pacific Islander,
1.5% were other races, and 10.6% were Multiracial. For participants 2 years through 5 years,
50.8% were male, 49.2% were female, 14.2% were Hispanic or Latino, 76.5% were White, 4.5%
were African American, 6.0% were Asian, 0.4% were American Indian or Alaska Native, 0.3%
were Native Hawaiian or Pacific Islander, 1.5% were other races, and 10.4% were Multiracial.
Demographic characteristics were similar among participants who received Moderna COVID-19
Vaccine and those who received placebo.
Participants were monitored for unsolicited adverse events for up to 28 days following each dose
and follow-up is ongoing. Serious adverse events and medically attended adverse events will be
recorded for the entire study duration.
As of February 21, 2022, among participants 6 months through 23 months of age who had
received at least 1 dose of vaccine or placebo (vaccine=1,761, placebo=589), unsolicited adverse
events that occurred within 28 days following each vaccination were reported by 49.3% of
participants (n=869) who received Moderna COVID-19 Vaccine and 48.2% of participants
(n=284) who received placebo. In these analyses, 83.1% of study participants 6 months through
23 months of age had at least 28 days of follow-up after Dose 2. Among participants 2 years
through 5 years of age who had received at least 1 dose of vaccine or placebo (vaccine=3,031,
placebo=1,007), unsolicited adverse events that occurred within 28 days following each
vaccination were reported by 40.0% of participants (n=1,212) who received Moderna COVID-19
Vaccine and 37.5% of participants (n=378) who received placebo. In these analyses, 89.3% of
study participants 2 years through 5 years of age had at least 28 days of follow-up after Dose 2.
reported by 1.5% of vaccine recipients and 0.2% of placebo recipients who were 6 months
through 23 months of age and 0.9% of vaccine recipients and <0.1% of placebo recipients who
were 2 years through 5 years of age. These events included lymphadenopathy, injection-site
lymphadenopathy, and vaccination-site lymphadenopathy which were plausibly related to
vaccination.
reported in 3.9% of vaccine recipients and 5.3% of placebo recipients who were 6 months
through 23 months of age and 3.5% of vaccine recipients and 2.5% of placebo recipients who
were 2 years through 5 years of age. Hypersensitivity events in the vaccine group included
injection site rash and injection site urticaria, which are likely related to vaccination. Delayed
injection site reactions that began >7 days after vaccination were reported in 1.2% of vaccine
recipients and no placebo recipients who were 6 months through 23 months of age and 1.4% of
vaccine recipients and <0.1% of placebo recipients who were 2 years through 5 years of age.
Delayed injection site reactions included pain, erythema, and swelling and are likely related to
vaccination.
During the 28-day follow-up period following any dose, events of abdominal pain (including
abdominal pain, abdominal pain upper, and abdominal discomfort) were reported by 0.7% of
vaccine recipients and 0.4% of placebo recipients who were 2 years through 5 years of age.
Currently available information is insufficient to determine a causal relationship with the
vaccine.
COVID-19 Vaccine.
As of February 21, 2022, serious adverse events were reported by 0.9% (n=15) of participants
who received vaccine and 0.2% (n=1) of participants who received placebo who were 6 months
through 23 months of age and 0.3% (n=9) of participants who received Moderna COVID-19
Vaccine and 0.2% (n=2) of participants who received placebo who were 2 years through 5 years
of age. In these analyses, 83.1% of study participants 6 months through 23 months of age had at
least 28 days of follow-up after Dose 2, and the median follow-up time for all participants was
68 days after Dose 2. In these analyses, 89.3% of study participants 2 years through 5 years of
age had at least 28 days of follow-up after Dose 2, and the median follow-up time for all
participants was 71 days after Dose 2.
In participants 6 months through 23 months of age who received the vaccine, a 1-year-old female
experienced serious adverse events of a Grade 3 fever 6 hours after Dose 1 and a febrile
convulsion 1 day after Dose 1. These events were considered related to vaccination. In
participants 2 years through 5 years of age who received Moderna COVID-19 Vaccine, none of
the events were considered related to vaccine.
A Third Primary Series Dose in Individuals with Certain Kinds of Immunocompromise
From an independent study (NCT04885907), in 60 adult participants who had undergone various
solid organ transplant procedures (heart, kidney, kidney-pancreas, liver, lung, pancreas) a median
of 3.57 years previously (range 1.99-6.75 years) who received a third vaccine dose (0.5 mL), the
adverse event profile was similar to that after the second dose and no Grade 3 or Grade 4 events
were reported.
6.2 Post-Authorization Experience
The following adverse reactions have been identified during post-authorization use of the
Moderna COVID-19 Vaccine. Because these reactions are reported voluntarily, it is not always
possible to reliably estimate their frequency or establish a causal relationship to vaccine
exposure.
Cardiac Disorders: myocarditis, pericarditis

Immune System Disorders: anaphylaxis, urticaria
Nervous System Disorders: syncope
8 REQUIREMENTS AND INSTRUCTIONS FOR REPORTING ADVERSE EVENTS

AND VACCINE ADMINISTRATION ERRORS12
See Overall Safety Summary (Section 6) for additional information.
The vaccination provider enrolled in the federal COVID-19 Vaccination Program is responsible
for the MANDATORY reporting of the listed events following Moderna COVID-19 Vaccine to
the Vaccine Adverse Event Reporting System (VAERS)
• Vaccine administration errors whether or not associated with an adverse event
• Serious adverse events* (irrespective of attribution to vaccination)
• Cases of myocarditis
• Cases of pericarditis
• Cases of Multisystem Inflammatory Syndrome (MIS) in adults and children
• Cases of COVID-19 that results in hospitalization or death
*Serious Adverse Events are defined as:

• Death;
• A life-threatening adverse event;
• Inpatient hospitalization or prolongation of existing hospitalization;
• A persistent or significant incapacity or substantial disruption of the ability to conduct
normal life functions;
• A congenital anomaly/birth defect;
• An important medical event that based on appropriate medical judgement may jeopardize
the individual and may require medical or surgical intervention to prevent one of the
12
Vaccination providers administering SPIKEVAX (COVID-19 Vaccine, mRNA) must adhere to the same
reporting requirements.
outcomes listed above.
Instructions for Reporting to VAERS
The vaccination provider enrolled in the federal COVID-19 Vaccination Program should
complete and submit a VAERS form to FDA using one of the following methods:
• Complete and submit the report online: https://vaers.hhs.gov/reportevent.html, or
• If you are unable to submit this form electronically, you may fax it to VAERS at 1-877-
721-0366. If you need additional help submitting a report, you may call the VAERS toll-
free information line at 1-800-822-7967 or send an email to [email protected].
IMPORTANT: When reporting adverse events or vaccine administration errors to

VAERS, please complete the entire form with detailed information. It is important that the
information reported to FDA be as detailed and complete as possible. Information to
include:
• Patient demographics (e.g., patient name, date of birth)
• Pertinent medical history
• Pertinent details regarding admission and course of illness
• Concomitant medications
• Timing of adverse event(s) in relationship to administration of Moderna COVID-19
Vaccine
• Pertinent laboratory and virology information
• Outcome of the event and any additional follow-up information if it is available at the
time of the VAERS report. Subsequent reporting of follow-up information should be
completed if additional details become available.
The following steps are highlighted to provide the necessary information for safety tracking:
1. In Box 17, provide information on Moderna COVID-19 Vaccine and any other vaccines
administered on the same day; and in Box 22, provide information on any other vaccines
received within one month prior.
2. In Box 18, description of the event:
a. Write “Moderna COVID-19 Vaccine EUA” as the first line
b. Provide a detailed report of vaccine administration error and/or adverse event. It
is important to provide detailed information regarding the patient and adverse
event/medication error for ongoing safety evaluation of this unapproved vaccine.
Please see information to include listed above.
3. Contact information:
a. In Box 13, provide the name and contact information of the prescribing healthcare
provider or institutional designee who is responsible for the report.
b. In Box 14, provide the name and contact information of the best doctor/healthcare
professional to contact about the adverse event.
c. In Box 15, provide the address of the facility where vaccine was given (NOT the
healthcare provider’s office address).
Other Reporting Instructions
Vaccination providers may report to VAERS other adverse events that are not required to be
reported using the contact information above.
To the extent feasible, report adverse events to ModernaTX, Inc. using the contact information
below or by providing a copy of the VAERS form to ModernaTX, Inc.
Email Fax number Telephone number
[email protected] 1-866-599-1342 1-866-MODERNA

(1-866-663-3762)
10 DRUG INTERACTIONS
There are no data to assess the concomitant administration of the Moderna COVID-19 Vaccine
with other vaccines.
11 USE IN SPECIFIC POPULATIONS
11.1 Pregnancy
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to
Moderna COVID-19 Vaccine during pregnancy. Women who are vaccinated with Moderna
COVID-19 Vaccine during pregnancy are encouraged to enroll in the registry by calling 1-866-
MODERNA (1-866-663-3762).
Risk Summary
All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general
population, the estimated background risk of major birth defects and miscarriage in clinically
recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on Moderna
COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-
associated risks in pregnancy.
In a developmental toxicity study, 0.2 mL of a vaccine formulation containing the same quantity
of nucleoside-modified messenger ribonucleic acid (mRNA) (100 mcg) and other ingredients
included in a single primary series dose of Moderna COVID-19 Vaccine for individuals 12 years
of age and older was administered to female rats by the intramuscular route on four occasions: 28
and 14 days prior to mating, and on gestation days 1 and 13. No vaccine-related adverse effects
on female fertility, fetal development, or postnatal development were reported in the study.
11.2 Lactation
Risk Summary
Data are not available to assess the effects of Moderna COVID-19 Vaccine on the breastfed
infant or on milk production/excretion.
11.3 Pediatric Use
Moderna COVID-19 Vaccine is authorized for use in individuals 6 months through 17 years of
age. This authorization is based on safety and effectiveness data in this age group and adults.
Moderna COVID-19 Vaccine is not authorized for use in individuals younger than 6 months of
age.
11.4 Geriatric Use
Clinical studies of Moderna COVID-19 Vaccine included participants 65 years of age and older
receiving vaccine or placebo, and their data contribute to the overall assessment of safety and
efficacy. In an ongoing Phase 3 clinical study (Study 1) of primary series dosing (0.5 mL),
24.8% (n=7,520) of participants were 65 years of age and older and 4.6% (n=1,399) of
participants were 75 years of age and older. Vaccine efficacy in participants 65 years of age and
older was 86.4% (95% CI 61.4, 95.2) compared to 95.6% (95% CI 90.6, 97.9) in participants 18
to <65 years of age [see Clinical Trial Results and Supporting Data for EUA (18.1)]. Overall,
there were no notable differences in the safety profiles observed in participants 65 years of age
and older and younger participants [see Overall Safety Summary (6.1)].
11.5 Use in Immunocompromised Individuals
Safety and effectiveness of Moderna COVID-19 Vaccine in individuals 6 months through 17

years of age with immunocompromise have been extrapolated from adult data. In an independent
study (Hall VG, Ferreira VH, Ku T et al. Randomized Trial of a Third Dose of mRNA-1273
Vaccine in Transplant Recipients. N Engl J Med 2021 DOI: 10.1056/NEJMc2111462;
NCT04885907), safety and effectiveness of a third 0.5 mL primary series dose of the Moderna
COVID-19 Vaccine have been evaluated in adult participants who received solid organ
transplants [see Overall Safety Summary (6.1) and Clinical Trial Results and Supporting Data
for EUA (18.3)]. The administration of a third primary series vaccine dose appears to be only
moderately effective in increasing antibody titers. Patients should be counseled to maintain
physical precautions to help prevent COVID-19. In addition, close contacts of
immunocompromised persons should be vaccinated, as appropriate for their health status.
13 DESCRIPTION
Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular

injection.
Each 0.5 mL dose of Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red
cap and a label with a light blue border contains 100 mcg of nucleoside-modified messenger
RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2
Wuhan-Hu-1 strain. Each 0.5 mL dose of the Moderna COVID-19 Vaccine supplied in a
multiple-dose vial with a red cap and a label with a light blue border contains the following
ingredients: a total lipid content of 1.93 mg (SM-102, polyethylene glycol [PEG] 2000
dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine
[DSPC]), 0.31 mg tromethamine, 1.18 mg tromethamine hydrochloride, 0.043 mg acetic acid,
0.20 mg sodium acetate trihydrate, and 43.5 mg sucrose.
Moderna COVID-19 Vaccine does not contain a preservative.
The vial stoppers are not made with natural rubber latex.
14 CLINICAL PHARMACOLOGY
14.1 Mechanism of Action
The nucleoside-modified mRNA in the Moderna COVID-19 Vaccine is formulated in lipid

particles, which enable delivery of the nucleoside-modified mRNA into host cells to allow
expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S
antigen, which protects against COVID-19.
18 CLINICAL TRIAL RESULTS AND SUPPORTING DATA FOR EUA
18.1 Efficacy of Two-Dose Primary Series in Participants 18 Years of Age and Older
Study 1 is an ongoing Phase 3 randomized, placebo-controlled, observer-blind clinical trial to

evaluate the efficacy, safety, and immunogenicity of the Moderna COVID-19 Vaccine in
participants 18 years of age and older in the United States (NCT04470427). Randomization was
stratified by age and health risk: 18 to <65 years of age without comorbidities (not at risk for
progression to severe COVID-19), 18 to <65 years of age with comorbidities (at risk for
progression to severe COVID-19), and 65 years of age and older with or without comorbidities.
Participants who were immunocompromised and those with a known history of SARS-CoV-2
infection were excluded from the study. Participants with no known history of SARS-CoV-2
infection but with positive laboratory results indicative of infection at study entry were included.
The study allowed for the inclusion of participants with stable pre-existing medical conditions,
defined as disease not requiring significant change in therapy or hospitalization for worsening
disease during the 3 months before enrollment, as well as participants with stable human
immunodeficiency virus (HIV) infection. A total of 30,420 participants were randomized equally
to receive 2 doses of the Moderna COVID-19 Vaccine or saline placebo 1 month apart.
Participants will be followed for efficacy and safety until 24 months after the second dose.
The primary efficacy analysis population (referred to as the Per-Protocol Set) included 28,207
participants who received two doses (0.5 mL at 0 and 1 month) of either Moderna COVID-19
Vaccine (n=14,134) or placebo (n=14,073) and had a negative baseline SARS-CoV-2 status. In
the Per-Protocol Set, 47.4% were female, 19.7% were Hispanic or Latino; 79.5% were White,
9.7% were African American, 4.6% were Asian, and 2.1% other races. The median age of
participants was 53 years (range 18-95) and 25.3% of participants were 65 years of age and
older. Of the study participants in the Per-Protocol Set, 18.5% were at increased risk of severe
COVID-19 due to at least one pre-existing medical condition (chronic lung disease, significant
cardiac disease, severe obesity, diabetes, liver disease, or HIV infection) regardless of age.
Between participants who received Moderna COVID-19 Vaccine and those who received
placebo, there were no notable differences in demographics or pre-existing medical conditions.
Efficacy Against COVID-19
COVID-19 was defined based on the following criteria: The participant must have experienced
at least two of the following systemic symptoms: fever (≥38ºC / ≥100.4°F), chills, myalgia,
headache, sore throat, new olfactory and taste disorder(s); or the participant must have
experienced at least one of the following respiratory signs/symptoms: cough, shortness of breath
or difficulty breathing, or clinical or radiographical evidence of pneumonia; and the participant
must have at least one NP swab, nasal swab, or saliva sample (or respiratory sample, if
hospitalized) positive for SARS-CoV-2 by RT-PCR. COVID-19 cases were adjudicated by a
Clinical Adjudication Committee.
The median length of follow-up for efficacy for participants in the study was 9 weeks post Dose
2. There were 11 COVID-19 cases in the Moderna COVID-19 Vaccine group and 185 cases in
the placebo group, with a vaccine efficacy of 94.1% (95% confidence interval of 89.3% to
96.8%).
Table 5: Primary Efficacy Analysis: COVID-19* in Participants 18 Years of Age and Older
Starting 14 Days After Dose 2 per Adjudication Committee Assessments – Per-Protocol Set
Moderna COVID-19 Vaccine Placebo

Participants COVID-19 Incidence Participants COVID-19 Incidence % Vaccine
(N) Cases Rate of (N) Cases Rate of Efficacy
(n) COVID-19 (n) COVID-19 (95% CI)†
per 1,000 per 1,000
Person- Person-
Years Years
14,134 11 3.328 14,073 185 56.510 94.1
(89.3, 96.8)
* COVID-19: symptomatic COVID-19 requiring positive RT-PCR result and at least two systemic symptoms or one
respiratory symptom. Cases starting 14 days after Dose 2. 
† VE and 95% CI from the stratified Cox proportional hazard model. 
The subgroup analyses of vaccine efficacy are presented in Table 6.
Table 6: Subgroup Analyses of Vaccine Efficacy: COVID-19* Cases Starting 14 Days After
Dose 2 per Adjudication Committee Assessments – Per-Protocol Set

Age Participants COVID-19 Incidence Participants COVID-19 Incidence %
Subgroup (N) Cases Rate of (N) Cases Rate of Vaccine
(Years) (n) COVID-19 (n) COVID-19 Efficacy
per 1,000 per 1,000 (95%
Person- Person- CI)†
Years Years
18 to <65 10,551 7 2.875 10,521 156 64.625 95.6
(90.6, 97.9)
≥65 3,583 4 4.595 3,552 29 33.728 86.4

(61.4, 95.2)
* COVID-19: symptomatic COVID-19 requiring positive RT-PCR result and at least two systemic symptoms or one
respiratory symptom. Cases starting 14 days after Dose 2.
† VE and 95% CI from the stratified Cox proportional hazard model.
Severe COVID-19 was defined based on confirmed COVID-19 as per the primary efficacy
endpoint case definition, plus any of the following: Clinical signs indicative of severe systemic
illness, respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, SpO2 ≤93% on room
air at sea level or PaO2/FIO2 <300 mm Hg; or respiratory failure or ARDS (defined as needing
high-flow oxygen, non-invasive or mechanical ventilation, or ECMO), evidence of shock
(systolic blood pressure <90 mmHg, diastolic BP <60 mmHg or requiring vasopressors); or
significant acute renal, hepatic, or neurologic dysfunction; or admission to an intensive care unit
or death.
Among all participants in the Per-Protocol Set analysis, which included COVID-19 cases
confirmed by an adjudication committee, no cases of severe COVID-19 were reported in the
Moderna COVID-19 Vaccine group compared with 30 cases reported in the placebo group
(incidence rate 9.138 per 1,000 person-years). One PCR-positive case of severe COVID-19 in a
vaccine recipient was awaiting adjudication at the time of the analysis.
18.2 Effectiveness of Two-Dose Primary Series in Participants 12 Years Through 17 Years

of Age
Study 3 is an ongoing Phase 2/3 randomized, placebo-controlled, observer-blind, clinical trial to

evaluate the safety, reactogenicity, and effectiveness of the Moderna COVID-19 Vaccine in
adolescents ages 12 years through 17 years in the United States (NCT04649151). Participants
with a known history of SARS-CoV-2 infection were excluded from the study. A total of 3,732
participants were randomized 2:1 to receive 2 doses of the Moderna COVID-19 Vaccine or
saline placebo 1 month apart. Participants will be followed for effectiveness and safety until 1
year after the last dose.
Effectiveness in individuals 12 years through 17 years of age is based on a comparison of

immune responses in this age group to adults 18 years through 25 years of age.
In Study 3, an analysis was conducted of SARS-CoV-2 50% neutralizing titers and seroresponse
rates 28 days after Dose 2 in a subset of adolescents 12 years through 17 years of age in Study 3
and participants 18 years through 25 years of age in Study 1 who had no immunologic or
virologic evidence of prior SARS-CoV-2 at baseline. Noninferior immune responses as assessed
by geometric mean 50% neutralizing titers and seroresponse rates were demonstrated in a
comparison of adolescents 12 years through 17 years of age to participants 18 years through 25
years of age (Table 7).
Table 7: Summary of Geometric Mean Titer Ratio and Seroresponse Rate – Comparison of
Adolescents 12 Years Through 17 Years of Age to Participants 18 Years Through 25 Years
of Age – Per-Protocol Immunogenicity Subset
Moderna COVID-19 Vaccine

12 Years Through 18 Years Through 12 Years Through 17 Years/
17 Years 25 Years 18 Years Through 25 Years
n=340 n=296
Assay Time GMT GMT GMT Ratio Met
Point (95% CI)* (95% CI)* (95% CI)a Noninferiority
Objective
(Y/N)b
1401.7 1301.3 1.1
(1276.3, 1539.4) (1177.0, 1438.8) (0.9, 1.2)
SARS-CoV-2
28 days Difference in
neutralization
after Seroresponse Seroresponse Seroresponse Y
assay – ID50
Dose 2 % % Rate %
(titer)c
(95% CI)d (95% CI)d (95% CI)e
98.8 98.6 0.2
(97.0, 99.7) (96.6, 99.6) (-1.8, 2.4)
GMT = Geometric mean titers

n = Number of subjects with non-missing data at the corresponding timepoint
* Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values
greater than the upper limit of quantification (ULOQ) are replaced by the ULOQ if actual values are not available.
a
The log-transformed antibody levels are analyzed using an analysis of covariance (ANCOVA) model with the
group variable (adolescents in Study 3 and young adults in Study 1) as fixed effect. The resulted LS means,
difference of LS means, and 95% CI are back transformed to the original scale for presentation.
b
Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67, with a point
estimate of >0.8 and the lower bound of the 2-sided 95% CI for difference in seroresponse rate is greater than
-10%, with a point estimate of >-5%.
c
SARS-CoV-2 50% inhibitory dose (ID50) neutralization titers were determined using a SARS-CoV-2 Spike-
Pseudotyped Virus Neutralization Assay. Quantification of SARS-CoV-2 neutralizing antibodies utilizes lentivirus
particles expressing SARS-CoV-2 Spike protein on their surface and contains a firefly luciferase (Luc) reporter
gene for quantitative measurements of infection by relative luminescence units (RLU). Neutralization is measured
as the serum dilution at which RLU is reduced by 50% (ID50) relative to mean RLU in virus control wells virus
but after subtraction of mean RLU in cell control wells.
d
Seroresponse due to vaccination specific to pseudovirus neutralizing antibody ID50 titer at a subject level is
defined in protocol as a change from below LLOQ to equal or above LLOQ, or at least a 3.3-fold rise if baseline is
equal to or above LLOQ. An analysis done using seroresponse definition of at least 4-fold rise from baseline,
where baseline titers <LLOQ are set to LLOQ for the analysis, showed the same results. 95% CI is calculated
using the Clopper-Pearson method.
e
Difference in seroresponse rate 95% CI is calculated using the Miettinen-Nurminen (score) confidence limits.
A descriptive efficacy analysis evaluating confirmed COVID-19 cases accrued up to the data
cutoff date of May 8, 2021, was performed in 3,181 participants who received two doses (at 0
and 1 month) of either Moderna COVID-19 Vaccine (n=2,139) or placebo (n=1,042) and had a
negative baseline SARS-CoV-2 status (referred to as the Per-Protocol Set for Efficacy). In the
Per-Protocol Set for Efficacy, 51.5% were male, 48.5% were female, 11.0% were Hispanic or
Latino; 84.1% were White, 2.7% were African American, 6.3% were Asian, 0.5% were
American Indian or Alaska Native, <0.1% were Native Hawaiian or Pacific Islander, 0.9% were
other races, and 4.8% were Multiracial. Between participants who received Moderna COVID-19
Vaccine and those who received placebo, there were no notable differences in demographics.
The median length of follow up for efficacy for participants in the study was 53 days post Dose
2.
The efficacy information in adolescents 12 years through 17 years of age is presented in Table 8.
Table 8: Efficacy Analyses: COVID-19 in Participants 12 Years Through 17 Years of Age

Starting 14 Days After Dose 2 – Per-Protocol Set for Efficacy

N=2,139 N=1,042 % Vaccine
Efficacy
COVID-19 Incidence Rate COVID-19 Incidence Rate
(95% CI)*
Cases of COVID-19 Cases of COVID-19
(n) per 1,000 (n) per 1,000
Person-Years Person-Years
COVID-19 0 0 4 16.525 100.0
Case Definition 1a (28.9, NE)
COVID-19 1 1.939 7 28.981 93.3
Case Definition 2b (47.9, 99.9)
NE = Not estimable
* Vaccine efficacy defined as 1 — ratio of incidence rate (Moderna COVID-19 Vaccine vs. placebo). The 95% CI
of the ratio is calculated using the exact method conditional upon the total number of cases, adjusting for person-
years.
a
COVID-19 Case Definition 1: Participant must have experienced at least two of the following systemic symptoms:
fever (≥38°C / ≥100.4°F), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or the
participant must have experienced at least one of the following respiratory signs/symptoms: cough, shortness of
breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and the participant must have at
least one NP swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS- CoV-2
by RT-PCR.
b
COVID-19 Case Definition 2: Presence of at least one symptom from a list of COVID-19 symptoms and a positive
NP swab or saliva sample for SARS-CoV-2 by RT-PCR. Listed symptoms were fever (temperature >38°C /
≥100.4°F), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches, or body aches,
headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, or vomiting or diarrhea.
18.3 Immunogenicity of a Third Primary Series Dose in Individuals with Certain Kinds of
Immunocompromise
An independent randomized-controlled study has been conducted in 120 adult participants who
had undergone various solid organ transplant procedures (heart, kidney, kidney-pancreas, liver,
lung, pancreas) a median of 3.57 years previously (range 1.99-6.75 years). A third 0.5 mL
primary series dose of the Moderna COVID-19 Vaccine was administered to 60 participants
approximately 2 months after they had received a second dose; saline placebo was given to 60
individuals for comparison. Significant increases in levels of SARS-CoV-2 antibodies occurred
four weeks after the third dose in 55.0% of participants in the Moderna COVID-19 Vaccine
group (33 of 60) and 17.5% of participants in the placebo group (10 of 57).
19 HOW SUPPLIED/STORAGE AND HANDLING
The information in this section applies to the Moderna COVID-19 Vaccine that is supplied in
multiple-dose vials with red caps and labels with a light blue border. These multiple-dose vials
are supplied as follows:
NDC 80777-273-99 Carton of 10 multiple-dose vials, each vial containing 5.5 mL

NDC 80777-273-98 Carton of 10 multiple-dose vials, each vial containing 7.5 mL
During storage, minimize exposure to room light, and avoid exposure to direct sunlight and
ultraviolet light.
Frozen Storage
Store frozen between -50°C to -15°C (-58°F to 5°F).
Storage after Thawing

o Vials may be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30
days prior to first use.
o Vials may be stored between 8°C to 25°C (46°F to 77°F) for a total of 24 hours.
o Total storage at 8°C to 25°C (46°F to 77°F) must not exceed 24 hours.
Do not refreeze once thawed.
Thawed vials can be handled in room light conditions.
Transportation of Thawed Vials at 2°C to 8°C (36°F to 46°F)
If transport at -50°C to -15°C (-58°F to 5°F) is not feasible, available data support transportation
of one or more thawed vials for up to 12 hours at 2°C to 8°C (36°F to 46°F) when shipped using
shipping containers which have been qualified to maintain 2°C to 8°C (36°F to 46°F) and under
routine road and air transport conditions with shaking and vibration minimized. Once thawed and
transported at 2°C to 8°C (36°F to 46°F), vials should not be refrozen and should be stored at
2°C to 8°C (36°F to 46°F) until use.
20 PATIENT COUNSELING INFORMATION
Advise the recipient or caregiver to read the Vaccine Information Fact Sheet for Recipients and
Caregivers.
The vaccination provider must include vaccination information in the state/local jurisdiction’s
Immunization Information System (IIS) or other designated system. Advise recipient or caregiver
that more information about IISs can be found at:
https://www.cdc.gov/vaccines/programs/iis/about.html.
21 CONTACT INFORMATION
For general questions, send an email or call the telephone number provided below.
Email Telephone number

[email protected] 1-866-MODERNA
(1-866-663-3762)
This EUA Prescribing Information may have been updated. For the most recent Full EUA
Prescribing Information, please visit www.modernatx.com/covid19vaccine-eua.
Moderna US, Inc.

Cambridge, MA 02139
©2022 ModernaTX, Inc. All rights reserved.

Patent(s): www.modernatx.com/patents
Revised: Dec/8/2022

EUA Fact Sheet-PI-Providers-Prime-12y+

Uploaded by

Copyright:

Available Formats

EUA Fact Sheet-PI-Providers-Prime-12y+

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

EUA Fact Sheet-PI-Providers-Prime-12y+

Uploaded by

Copyright:

Available Formats

FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING

VACCINE (VACCINATION PROVIDERS)

SPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made

SPIKEVAX (COVID-19, mRNA) and Moderna COVID-19 Vaccine supplied in multiple-

SUMMARY OF INSTRUCTIONS FOR COVID-19 VACCINATION PROVIDERS

The Moderna COVID-19 Vaccine is a suspension for intramuscular injection.

DOSAGE AND ADMINISTRATION

Storage and Handling

Storage after Thawing

Do not refreeze once thawed.

Thawed vials can be handled in room light conditions.

Transportation of Thawed Vials at 2°C to 8°C (36°F to 46°F)

Preparation for Administration

Multiple-Dose Thaw in Refrigerator Thaw at Room Temperature

5.5 mL Thaw between 2°C to 8°C (36°F Alternatively, thaw between

• After thawing, do not refreeze.

Management of Acute Allergic Reactions

Myocarditis and Pericarditis

Limitations of Vaccine Effectiveness

Adverse Reactions in Clinical Trials

USE WITH OTHER VACCINES

INFORMATION TO PROVIDE TO VACCINE RECIPIENTS/CAREGIVERS

MANDATORY REQUIREMENTS FOR MODERNA COVID-19 VACCINE

3. The vaccination provider must include vaccination information in the state/local

Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html.

*Serious adverse events are defined as:

Email Fax number Telephone number

[email protected] 1-866-599-1342 1-866-MODERNA

Website Telephone number

FEDERAL COVID-19 VACCINATION PROGRAM

AUTHORITY FOR ISSUANCE OF THE EUA

COUNTERMEASURES INJURY COMPENSATION PROGRAM

Moderna US, Inc.

©2022 ModernaTX, Inc. All rights reserved.

END SHORT VERSION FACT SHEET

MODERNA COVID-19 VACCINE

FULL EUA PRESCRIBING INFORMATION: CONTENTS* 11 USE IN SPECIFIC POPULATIONS

FULL EMERGENCY USE AUTHORIZATION (EUA) PRESCRIBING INFORMATION

2 DOSAGE AND ADMINISTRATION

For intramuscular injection only.

Thawing Instructions for Moderna COVID-19 Vaccine Multiple-Dose Vials with

Multiple-Dose Thaw in Refrigerator Thaw at Room Temperature

5.5 mL Thaw between 2°C to 8°C (36°F Alternatively, thaw between

• After thawing, do not refreeze.

Administer the Moderna COVID-19 Vaccine intramuscularly.

2.3 Dose and Schedule

3 DOSAGE FORMS AND STRENGTHS

5 WARNINGS AND PRECAUTIONS

5.1 Management of Acute Allergic Reactions

Appropriate medical treatment to manage immediate allergic reactions must be immediately

5.2 Myocarditis and Pericarditis

Postmarketing data with Moderna COVID-19 Vaccine demonstrate increased risks of

Syncope (fainting) may occur in association with administration of injectable vaccines.

5.4 Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may

5.5 Limitations of Vaccine Effectiveness

6 OVERALL SAFETY SUMMARY

It is MANDATORY for vaccination providers to report to the Vaccine Adverse Event

6.1 Clinical Trials Experience

Study 1 (NCT04470427) is a Phase 3 randomized, placebo-controlled, observer-blind clinical